Inventor · disambiguated record
Lianhai Li
Also filed as: LI LIANHAI
11 granted patents·11 pending applications·123 citations·filing 2003–2019
89Inventor score
Files withBERTHELETTE CARL4MERCK FROSST CANADA INC3MERCK FROSST CANADA LTD2MERCK FROSST COMPANY2NANJING ALLGEN PHARMA CO LTD2
Top patents by PatentIndex Score
22 records- 0188US7622501B2Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST CANADA INC·Filed 2005·Granted Nov 24, 2009·14 cites·15 claims
- 0288US7622502B2Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST CANADA INC·Filed 2005·Granted Nov 24, 2009·14 cites·15 claims
- 0387US7199154B2Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST COMPANY·Filed 2003·Granted Apr 3, 2007·42 cites·18 claims
- 0487US7169809B2Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST COMPANY·Filed 2004·Granted Jan 30, 2007·35 cites·24 claims
- 0584US9814719B2Methods and compositions for treating bacterial infectionCURATORS OF THE UNIV OF MISSOURI·Filed 2016·Granted Nov 14, 2017·3 cites·19 claims
- 0682US7618994B2Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA LTD·Filed 2007·Granted Nov 17, 2009·3 cites·23 claims
- 0778US9345905B2Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agentsNANJING ALLGEN PHARMA CO LTD·Filed 2012·Granted May 24, 2016·5 cites·11 claims
- 0877US7317036B2Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA INC·Filed 2003·Granted Jan 8, 2008·6 cites·6 claims
- 0967US2010081696A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2009·Application pending·0 cites
- 1062US10605852B2Concomitant impedance protection method for half-wavelength transmission lineCHINA ELECTRIC POWER RES INSTITUTE COMPANY LIMITED·Filed 2016·Granted Mar 31, 2020·1 cites·7 claims
- 1157US2006069148A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2005·Application pending·0 cites
- 1256US2012115921A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentBERTHELETTE CARL·Filed 2012·Application pending·0 cites
- 1355US2003158246A1Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentFiled 2003·Application pending·0 cites
- 1450US2010137371A1Novel Pharmaceutical CompoundsBERTHELETTE CARL·Filed 2006·Application pending·0 cites
- 1549US2010298347A1Substituted 2-naphthoic acids as antagonists of gpr105 activityMERCK FROSST CANADA LTD·Filed 2008·Application pending·0 cites
- 1647US9226923B2Spirocyclic molecules as protein kinase inhibitorsWANG ZHAOYIN·Filed 2012·Granted Jan 5, 2016·0 cites·10 claims
- 1745US2007054951A1Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonistsLI LIANHAI·Filed 2004·Application pending·0 cites
- 1842US2010179173A1Substituted fused pyrimidines as antagonists of gpr105 activityGUAY DANIEL·Filed 2008·Application pending·0 cites
- 1941US9458162B2Cyclic molecules as bruton's tyrosine kinase inhibitorsNANJING ALLGEN PHARMA CO LTD·Filed 2013·Granted Oct 4, 2016·0 cites·6 claims
- 2040US2008242722A1Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular EventsDUFRESNE CLAUDE·Filed 2005·Application pending·0 cites
- 2138US2019210973A1Compounds and methods for treatment of cystic fibrosisUNIV MISSOURI·Filed 2019·Application pending·0 cites
- 2227US2011301143A1Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturaseISABEL ELISE·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lianhai Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →